tbuckley/cabot-search huggingface dataset:
State laws and regulations covering fertility preservation for cancer patients
Authors: S. T. Vadaparampil, K. M. Lowrey, C. A. Miree, S. S. Eidson, J. B. Watson, G. P. Quinn
Journal: Journal of Clinical Oncology (2009)

9509 Background: Studies suggest up to 90% of cancer patients in their reproductive years may be at risk of permanent infertility. Yet, few utilize fertility preservation (FP) technologies. One barrier identified by patients and providers is the lack of insurance coverage for FP services. The goal of this study was to examine codified state policies related to infertility and assess their implications for cancer patients at risk for infertility due to treatment. Methods: A keyword search string was developed to identify statutes and administrative regulations of insurance coverage for FP in effect as of July 1, 2008, for the 50 states and the District of Columbia. Laws addressing a more general population but pertaining to cancer patients (e.g., policies addressing in vitro fertilization), were compiled using Lexis-Nexis. Data were analyzed by reviewing the “plain meaning” of the text, legislative/administrative history, and annotated case law. Legal reasoning and common rules of statutory construction and legislative interpretation were used. Findings were recorded using qualitative and dichotomous, quantitative indicators. Quality assurance reviews of all data were conducted and findings were compared with secondary sources. Results: As of July 1, 2008, 15 states (29.4%) had laws relating to insurance coverage for infertility or in vitro fertilization (IVF) procedures. Nine states (17.6%) mandated some type of insurance coverage for infertility treatments, 5 of which defined infertility. One state (CA) mandated an offer of coverage for infertility, but did not define it. For laws concerning IVF, 7 states (13.7%) mandated coverage; 1 state (TX) mandated an offer of coverage; and 2 states (CA and IL) specifically excluded IVF from a mandatory offer of coverage. No state laws or regulations addressed insurance coverage for FP methods specific to cancer patients. Conclusions: There is a strong argument for policies that require coverage for infertility of cancer survivors and FP options prior to treatment similar to mandatory coverage requirements for other side effects experienced by cancer patients (e.g., lymphedema, alopecia). No significant financial relationships to disclose.
Identification Of Low Risk Group In Infants With Acute Lymphoblastic Leukemia By Flow Cytometric Minimal Residual Disease Measurement At Day 15 Of Interfant-99 and Interfant-06 Protocols Treatment
Authors: Alexander Popov, Barbara Buldini, Paola de Lorenzo, Emanuella Giarin, Annamaria Di Meglio, Franco Locatelli, Rosanna Parasole, Larisa Fechina, Grigory Tsaur, Andrea Biondi, Maria Grazia Valsecchi, Giuseppe Basso
Journal: Blood (2013)
Results of an Ontario Clinical Oncology Group (OCOG) prospective cohort study on the use of FDG PET/CT to predict the need for neck dissection following radiation therapy of head and neck cancer (HNC).
Authors: J. N. Waldron, R. W. Gilbert, L. Eapen, A. Hammond, D. I. Hodson, A. Hendler, B. Perez-Ordonez, C. Gu, J. A. Julian, D. H. Julian, M. N. Levine
Journal: Journal of Clinical Oncology (2011)

5504 Background: A significant proportion of node-positive HNC patients will have residual nodes visible on CT following curative radiation therapy +/- concurrent chemotherapy (RT+/-Chemo). A third of these will harbor residual cancer and can be cured by neck dissection (ND). This study examines the ability of PET/CT to detect residual nodal cancer following RT+/-Chemo in HNC patients. Methods: This prospective multi-center study was conducted at 4 regional cancer centers in Ontario. Eligible patients had squamous cell carcinomas with N2 or N3 neck disease. They were treated curatively with RT+/-Chemo to include full radiation dose to nodes deemed involved by tumor. Contrast enhanced CT scans and PET/CT were performed prior to and 8-10 weeks following RT+/-Chemo. Patients with residual nodes >1cm axial dimension on CT were mandated to undergo ND within 4 weeks of imaging. The pathologic results of ND were correlated with post treatment imaging. Patients were followed for neck recurrence for 2 years. Results: 399 patients were enrolled: 335 (84%) male and 64 (16%) female, with a mean age of 57 years (range: 27-84). Primary sites included: oropharynx 301 (75%), oral cavity 35 (9%), hypopharynx 31 (8%), larynx 31 (8%) and unknown primary site 56 (14%). T and N categories were T0 58 (15%), T1-T2 191 (48%), T3-T4 146 (37%), N2a 58 (15%), N2b 173 (43%), N2c 130 (33%) and N3 38 (10%). 325 patients have been followed for at least 18 months. 350 patients completed post-treatment PET/CT at a mean of 9.2 weeks (range: 4-19). Results for 152 patients having ND are shown in the table. PET/CT sensitivity was significantly lower than that for CT (53% vs 94%; p<0.001). Of the 201 patients who did not have ND, 8/201 (4%) had neck recurrence on follow-up. Post-treatment PET/CT was positive in 4/8 (50%) of these, and it was also positive in 24/193 (12%) who had no neck recurrence on follow-up. Conclusions: PET/CT performed 8-10 weeks following RT+/-Chemo is not a reliable indicator of residual nodal disease and should not be used to determine the need for ND. Pathology Sens % Spec % PPV % NPV % + − PET/CT + 27 35 53 (40-66)* 65 (56-74)* 44 (32-56)* 73 (63-81)* − 24 66 * 95% CI
Population Pharmacological Profiles Of AML Treatments In Patient Samples By Automated Flow Cytometry; A Bridge To Individualized Medicine
Authors: Joan Ballesteros, Pau Montesinos, Federico Moscardo, David Martinez, Miguel Angel Sanz, Joaquin Martinez Lopez, Raimundo Garcia Boyero, Jaime Pérez de Oteyza, Pascual Fernandez, Josefina Serrano, Angeles Fernandez, Pilar Herrera, Arancha Alonso, Ataulfo Gonzalez, Concepcion Bethancourt, Esperanza Lavilla, Juan Antonio Vera, Begoña Navas, Gabriela Rodriguez, Juan Antonio Lopez, Santiago Jimenez Bravo de Laguna, Adriana Simiele, Bernardo Gonzalez, Jose Angel Hernandez Rivas, Raul Cordoba, Consolación Rayón, Carmen Burgaleta, Jordi Sierra, Daniel Primo, Pilar Hernandez-Campo, Julian Gorrochategui, Jose L. Rojas, Belen Liebana, Rocio Lopez, Troconiz Iñaki, Ignacio Ortega, Teresa A. Bennett
Journal: Blood (2013)
TCTAP A-144 Effect of Anti–Proliferative Drug Concentration on Short Term Outcomes in Patients Undergoing Second Generation Drug Eluting Stent Implantation
Authors: Tapan Ghose, Supratiksh Yadav, Kuldeep Arora, Bharat Kukreti, Satya Nand Pathak
Journal: Journal of the American College of Cardiology (2016)
Clause in junior contract that allows terms to vary is “a form of slavery,” says barrister
Authors: Clare Dyer
Journal: BMJ (2016)

A far reaching clause in the new NHS contract for junior doctors in England allowing employers to vary the terms and conditions unilaterally is highly unusual and could well be successfully challenged if acted on, employment law experts say.

Under the clause, NHS employers “reserve the right from time to time in our absolute discretion to review, revise, amend or replace any term or condition of this contract and to introduce new policies and procedures, …
FDG PET/CT in Hepatoid Adenocarcinoma of the Lung
Authors: Shouyang Wang, Mengxi Li, Huai Chen, Jianyu Li, Qingsi Zeng
Journal: Clinical Nuclear Medicine (2016)

A right upper lung mass was incidentally found on a chest radiograph in a routine health examination in a 56-year-old man. The mass showed mild heterogeneous enhancement on contrast chest CT images and intense FDG uptake on PET/CT images. Pathological examination demonstrated hepatoid adenocarcinoma in the lung.
Perioperative Outcomes, Health Care Costs, and Survival After Robotic-assisted Versus Open Radical Cystectomy: A National Comparative Effectiveness Study
Authors: Jim C. Hu, Bilal Chughtai, Padraic O’Malley, Joshua A. Halpern, Jialin Mao, Douglas S. Scherr, Dawn L. Hershman, Jason D. Wright, Art Sedrakyan
Journal: European Urology (2016)
Sustained Gene Expression in Retrovirally Transduced, Engrafting Human Hematopoietic Stem Cells and Their Lympho-Myeloid Progeny
Authors: Linzhao Cheng, Changchun Du, Catherine Lavau, Shirley Chen, Jie Tong, Benjamin P. Chen, Roland Scollay, Robert G. Hawley, Beth Hill
Journal: Blood (1998)
Rictor/mTORC2 Drives Progression and Therapeutic Resistance of <i>HER2</i>-Amplified Breast Cancers
Authors: Meghan Morrison Joly, Donna J. Hicks, Bayley Jones, Violeta Sanchez, Monica Valeria Estrada, Christian Young, Michelle Williams, Brent N. Rexer, Dos D. Sarbassov, William J. Muller, Dana Brantley-Sieders, Rebecca S. Cook
Journal: Cancer Research (2016)

HER2 overexpression drives Akt signaling and cell survival and HER2-enriched breast tumors have a poor outcome when Akt is upregulated. Akt is activated by phosphorylation at T308 via PI3K and S473 via mTORC2. The importance of PI3K-activated Akt signaling is well documented in HER2-amplified breast cancer models, but the significance of mTORC2-activated Akt signaling in this setting remains uncertain. We report here that the mTORC2 obligate cofactor Rictor is enriched in HER2-amplified samples, correlating with increased phosphorylation at S473 on Akt. In invasive breast cancer specimens, Rictor expression was upregulated significantly compared with nonmalignant tissues. In a HER2/Neu mouse model of breast cancer, genetic ablation of Rictor decreased cell survival and phosphorylation at S473 on Akt, delaying tumor latency, penetrance, and burden. In HER2-amplified cells, exposure to an mTORC1/2 dual kinase inhibitor decreased Akt-dependent cell survival, including in cells resistant to lapatinib, where cytotoxicity could be restored. We replicated these findings by silencing Rictor in breast cancer cell lines, but not silencing the mTORC1 cofactor Raptor (RPTOR). Taken together, our findings establish that Rictor/mTORC2 signaling drives Akt-dependent tumor progression in HER2-amplified breast cancers, rationalizing clinical investigation of dual mTORC1/2 kinase inhibitors and developing mTORC2-specific inhibitors for use in this setting. Cancer Res; 76(16); 4752-64. ©2016 AACR.
To Cure Sometimes, to Relieve Often, to Comfort Always
Authors: Andre Kumar, Nazima Allaudeen
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Granulation Tissue Eroding the Subchondral Bone Also Promotes New Bone Formation in Ankylosing Spondylitis
Authors: Janine Bleil, Rene Maier, Axel Hempfing, Joachim Sieper, Heiner Appel, Uta Syrbe
Journal: Arthritis & Rheumatology (2016)

We previously suggested that fibroblast-rich granulation tissue eroding the subchondral bone is instrumental in the joint remodeling that occurs in ankylosing spondylitis (AS). The purpose of this study was to determine if this granulation tissue also carries bone-forming capabilities, which we approached by searching for bone-forming cells (hypertrophic chondrocytes, osteoblasts) in its vicinity. We also assessed adipogenic tissue transformation, which has been suggested to be an intermediate feature in AS bone formation based on imaging studies.The facet joints of AS patients, osteoarthritis (OA) patients, and autopsy subjects (controls) were screened for subchondral granulation tissue. We searched for hypertrophic chondrocytes by assessing RUNX-2, type X collagen, and matrix metalloproteinase 13 (MMP-13) expression, for osteoblasts by analyzing RUNX-2, CD56, and type I collagen expression, as well as for signs of new bone formation. Adipocytes and lipid accumulation were assessed in Safranin O-stained sections.In the joints of AS and OA patients, RUNX-2-positive cells were found to be lining the granulation tissue. These cells coexpressed type I collagen but lacked type X collagen and MMP-13 expression, confirming their osteoblastic nature. In 91% of AS joints and in 20% of OA joints (P < 0.05), we observed foci of new bone formation at contact zones between the granulation tissue and the cartilage. Joints containing bony spots showed greater replacement of the adjacent bone marrow by granulation tissue than did joints without bone formation (P < 0.05). The granulation tissue often contained adipocytes and lipid accumulations. Replacement of the subchondral bone marrow by fat tissue was also frequently found but was not associated with new bone formation.The subchondral granulation tissue carries osteoblasts, which promote new bone formation, leading to intraarticular ankylosis of the facet joints in AS.
Paediatric sepsis: the race is on
Authors: Anthony Cohn
Journal: BMJ (2016)

Repeated studies show that most children who die of sepsis have presented to a doctor in the preceding 48 hours. The fear of every doctor working with children is sending home a child only for them to return moribund or worse, and every new paediatric trainee cites being able to recognise a sick child as one of the main goals of their …
Clinical Experience with 31 Consecutive Cases of Surgical Intervention for the Control of Bleeding from the Upper Gastrointestinal Tract
Authors: James M. Parker
Journal: New England Journal of Medicine (1958)

IN 1933 intense interest in the problem of massive bleeding from the upper gastrointestinal tract was stimulated by the report of Allen and Benedict.1 These authors found that approximately half the patients over forty-five years of age who bleed from peptic ulcer have massive hemorrhage and that, if treated expectantly, a third will die. Allen,2 Hinton3 and Finsterer4 reported series in which patients subjected to gastric resection almost immediately after onset of hemorrhage showed a significantly reduced mortality whereas in those with delay in surgical intervention the figure remained about 30 per cent. In 1948 Dunphy and Hoerr,5 by proving . . .
<i>TP53</i>Gene and Cancer Resistance in Elephants
Authors: Raymond P. Perez, Takefumi Komiya
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prospective Phase III Trial Of Valproic Acid (VPA) In Combination With All-Trans Retinoic Acid (ATRA) and Intensive Induction Therapy For AML In Older Patients: Final and Molecular Subset Analyses Of The AMLSG 06-04 Study
Authors: Michela Giulia Tassara, Konstanze Döhner, Peter Brossart, Gerhard Held, Katharina Goetze, Heinz-August Horst, Mark Ringhoffer, Claus-Henning Kohne, Stephan Kremers, Aruna Raghavachar, Gerald Wulf, Heinz Kirchen, David Nachbaur, Hans-Günter Derigs, Mohammed Wattad, Elisabeth Koller, Wolfram Brugger, Axel C. Matzdorff, Richard Greil, Gerhard Heil, Daniela Späth, Peter Paschka, Verena I. Gaidzik, Martin Göttlicher, Hartmut Döhner, Richard F. Schlenk
Journal: Blood (2013)
Abstract 15067: Incidence and Outcomes of Neonates With Congenital Heart Disease Complicated by Necrotizing Enterocolitis
Authors: Pirouz Shamszad, Shaine A Morris, Deipanjan Nandi, Andrew T Costarino, Bradley S Marino, Joseph W Rossano
Journal: Circulation (2015)

Introduction: The management of neonates with congenital heart disease (CHD) may be complicated by necrotizing enterocolitis (NEC), however, there is limited multicenter data describing the incidence and outcomes of NEC in the CHD population. Objective: We aimed to assess the incidence and risk factors for the development of NEC in neonates with major CHD and the impact on survival. Methods: A retrospective cohort study of neonates with CHD was performed for all index hospitalizations of neonates (&lt;28 days) with major CHD between 2004 and 2014 using the Pediatric Health Information System database. The diagnosis of NEC was determined by the presence of ICD-9 code 777.5x. The incidence of NEC was determined as were risk factors for the development of NEC. Mortality was the primary outcome measure. Results: Of 38770 neonates with major CHD, 1448 (3.6%) were diagnosed with NEC. The rate of NEC varied between 0-8% by hospital and was not associated with hospital volume (p=0.4). Among neonates with a single, major CHD diagnosis, the rate of NEC was 6% in hypoplastic left heart syndrome (HLHS), 6% in truncus arteriosus (TA) , 4% in tetralogy of Fallot (TOF), 3% in aortic arch obstruction (AO), and 2% in transposition of the great arteries (TGA); these diagnoses accounted for 47% of all NEC. Prematurity and chromosomal anomalies were independently associated with the diagnosis of NEC (p≤0.01 for both). Unadjusted mortality among neonates with NEC was 24% compared to 12% in neonates without NEC (OR 2.4, 95%CI 2.1-2.7). When evaluating changes in adjusted mortality associated with NEC by CHD diagnosis, TOF mortality increased from 8% to 16% (p&lt;.01), TGA increased from 5% to 21% (p&lt;0.01), AO increased from 6% to 20% (p&lt;0.01), HLHS increased from 22% to 28% (p=.07), and TA decreased from 13% to 12% (p=0.7). Median LOS was higher in neonates with NEC than without NEC (54d [IQR 31-93] vs. 18d [IQR 9-34], p&lt;0.01) as was median hospital charge ($600k [IQR 310k-1.1m] vs. $220k [IQR 100k-430k], p&lt;0.01). Conclusions: The incidence of NEC among neonates with major CHD is highest in HLHS and TA. NEC is associated with significantly higher hospital mortality, LOS, and charges. Determining modifiable factors associated with NEC may allow for interventions to reduce morbidity in this population.
CPORT: Effective partnership working to optimize chemotherapy capacity in the UK
Authors: A. A. Basar, J. Whittome
Journal: Journal of Clinical Oncology (2009)

e20687 Background: Capacity planning in a complex environment such as a chemotherapy unit is a difficult task; combined with ever increasing patient numbers and limited budgets, time and ability to plan is scarce. This project demonstrates how partnership working between the pharmaceutical industry and NHS service providers can optimise chemotherapy capacity in UK centres. Methods: CPORT stands for “Chemotherapy-Planning Oncology Resource Tool”. The tool is a simulator allowing chemotherapy planners to model how different drugregimens, patient flows, resource levels and ways of working influence the performance of a chemotherapy unit in terms of how many patients are treated, how long they wait, and how much care they receive. A small dedicated team at Roche has been working closely with a team of NHS Facilitators, with the full approval and backing of the National Cancer Action Team. The integrated team have been helping with the roll out of the tool, focusing on supporting cancer units implement CPORT from concept through change and sharing best practice. Results: To date more than 2800 simulations have been run through the tool. Service redesign options have been assessed in minutes and hours, as opposed to weeks and months. The simulator has enabled combinations of several service improvement initiatives to be modelled simultaneously, giving managers the ability to model cancer service delivery in a simulated online environment which is both cost free and risk free. Early results include the better coordination of pharmacy and nursing workload to optimise the available capacity; utlising CPORT to plan the merger of two units and model subsequent resource requirements; modelling the relocation of a unit and predicted caseload of patients. Conclusions: This model represents a successful new form of partnership working between the NHS and the industry to increase capacity within chemotherapy services. It promotes equity of service, better access and an improved experience for all patients receiving chemotherapy, embedding and sustaining the concept of capacity planning within the clinical service. No significant financial relationships to disclose.
Queen's Speech: Mental health bill will be subject to pre-legislative scrutiny
Authors: Roger Dobson
Journal: BMJ (2003)

A revised mental health bill for England and Wales is to be brought forward as soon as possible and will be subject to pre-legislative scrutiny.

The government also plans to monitor the use of compulsion, an area of the draft bill published last year that proved highly controversial (BMJ 2003;326: 406-7 [PubMed]).

The bill, described as the first major overhaul relating to mental health since the 1950s, was said to remove a loophole that allowed people with dangerous and severe personality disorders to avoid treatment by arguing that they got no benefit from it. But critics of the draft bill said that it would mean that many people with incurable personality disorders could be locked up indefinitely in secure mental hospitals, without the need for evidence that they had committed a crime.

The bill was expected to be brought to the last parliamentary session, but it was not. Now the health secretary, John Reid, says that the government is fully committed to reforming mental health legislation.

He said, “We must make significant improvements to patient safeguards, provide a modern framework of legislation in line with modern patterns of care and treatment and human rights law, and protect public safety by enabling patients to get the right treatment at the right time.”

“In order to achieve our objectives it will be vital to get the legislation right. To that end it is important that a strong part is played by parliament in scrutinising the bill.”

Dr Tony Zigmond, vice president of the Royal College of Psychiatrists, said there were still concerns: “We hope that the provisions in the new legislation will be very significantly changed, particularly those on the definition of mental disorder and the criteria for compulsion.”

The chief executive of MIND (a mental health charity), Richard Brook, said: “We welcome the commitment to put the proposed bill before pre-legislative scrutiny. Unless the needs and concerns of people with mental health problems are properly taken into account in this process, and reflected in any subsequent legislation, they [legislators] will once more be neglecting their most important stakeholders.”